Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Immunogenicity and Safety of Freeze-Dried Human Rabies Vaccine (Vero Cell) in Patients Infected With Human Immunodeficiency Virus (HIV)

6 novembre 2026 mis à jour par: Liaoning Chengda Biotechnology CO., LTD

This is a prospective, open-label, randomized controlled clinical trial designed to evaluate rabies virus neutralizing antibody responses to rabies vaccination among patients infected with human immunodeficiency virus (HIV). Eligible participants will be divided into two groups according to baseline CD4+ T cell count before randomization. Within each group, participants will be randomly assigned to one of two different rabies vaccination regimens for simulated post-exposure prophylaxis. Blood samples will be collected before vaccination and at scheduled time points after vaccination. Rabies virus neutralizing antibody titers will be tested to assess the seroconversion rate and geometric mean concentration (GMC). Adverse events after vaccination will also be recorded.

Aperçu de l'étude

Statut

Recrutement

Les conditions

Description détaillée

This prospective, open-label, randomized controlled clinical trial will enroll HIV-infected patients aged 18-60 years who are receiving antiretroviral therapy (ART). A total of 160 eligible participants will be divided into two groups based on baseline CD4+ T cell count (<350 cells/mm³ vs. ≥350 cells/mm³) before randomization, with 80 subjects in each group. Within each group, participants will be randomized in a 1:1 ratio to receive freeze-dried human rabies vaccine (Vero cell) under the Zagreb regimen or the Essen regimen.

Serum samples will be collected at scheduled time points according to different vaccination regimens. For participants assigned to the Zagreb regimen, blood samples will be obtained on Day 0, Day 14, Day 35, and three months after completion of the full vaccination course. For participants assigned to the Essen regimen, blood samples will be collected on Day 0, Day 14, Day 28, Day 42, and three months after completion of the full vaccination course. Rabies virus neutralizing antibody titers will be measured for all collected serum samples, and seroconversion rate and GMC will be calculated to assess immune responses at each predefined time point.

Participants with rabies virus neutralizing antibody titers lower than 0.5 IU/mL at 14 days after completion of the full vaccination course will receive booster vaccination on Day 0 and Day 3. Blood samples will be collected 14 days after booster administration to measure rabies virus neutralizing antibody titers. Seroconversion rate and GMC will be calculated to evaluate immune responses after booster vaccination.

Adverse events will be monitored throughout the study. All immediate adverse events occurring within 30 minutes after each dose will be recorded. Solicited adverse events will be monitored for 7 days after each dose. Unsolicited adverse events will be monitored from day 8 to day 14 following each dose.

Type d'étude

Interventionnel

Inscription (Estimé)

160

Phase

  • Phase 4

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

  • Nom: Li Tong
  • Numéro de téléphone: +86 15811315908
  • E-mail: 14877107@qq.com

Lieux d'étude

    • Guangxi
      • Nanning, Guangxi, Chine, 530028
        • Recrutement
        • Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention
        • Contact:
        • Chercheur principal:
          • Jingxia Luo
      • Nanning, Guangxi, Chine, 530012
        • Recrutement
        • The Fourth People's Hospital of Nanning City
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 60 ans (Adulte)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • HIV-infected participants aged 18 to 60 years, able to provide valid identification.
  • Normal liver and renal function confirmed by laboratory testing within 7 days prior to screening or on the day of screening.
  • Receiving antiretroviral therapy (ART) for at least 6 months with a stable CD4+ T cell count ≥350 cells/mm³; or receiving ART for at least 6 months with a CD4+ T cell count <350 cells/mm³ and previously treated, well-controlled opportunistic infections (no clinical signs of active opportunistic infection, normal routine blood tests, and normal liver and renal test results).
  • No active opportunistic infection or tumor, no history of drug allergy, and no other severe acute or chronic illnesses.
  • Willing to participate in the study voluntarily and provide written informed consent.
  • Participants are able to attend all scheduled visits as required by the protocol, with no plans for long term absence or relocation away from the study site.
  • Axillary temperature ≤37.2℃ at screening.

Exclusion Criteria:

  • History of rabies vaccination.
  • History of receiving any blood, blood products or immunoglobulin within 3 months prior to the first vaccine dose, or plans to use these products within 1 month after the last vaccine dose.
  • Receipt of immunosuppressive therapy within 3 months prior to enrollment, including continuous administration of systemic glucocorticoids (for 14 days or longer at a dose of ≥20 mg per day).
  • Participating in another clinical trial (vaccine or drug) or planning to participate in another clinical trial during the course of this trial.
  • Confirmed pregnancy (positive urine pregnancy test at enrollment), or women of childbearing potential planning to become pregnant within 2 months.
  • History of allergy to any component of the study vaccine, including excipients and antibiotics.
  • Presence of any acute disease, or chronic disease in active phase.
  • History of serious adverse events following administration of other vaccines.
  • Any condition that may interfere with study outcomes or study procedures, as assessed by the investigator.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: La prévention
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Zagreb regimen (CD4+ T cell count ≥350 cells/mm³)

Eligible HIV-infected participants on stable antiretroviral therapy and with a baseline CD4+ T cell count ≥350 cells/mm³ will receive 2 doses of rabies vaccine on day 0, 1 dose on day 7, and 1 dose on day 21, for a total of 4 doses.

0.5mL for each dose, manufactured by Liaoning Chengda Biotechnology CO., LTD, administered by intramuscular injection into the deltoid muscle of the lateral upper arm.

Autres noms:
  • VITESSE
Expérimental: Essen regimen (CD4+ T cell count ≥350 cells/mm³)

Eligible HIV-infected participants on stable antiretroviral therapy and with a baseline CD4+ T cell count ≥350 cells/mm³ will receive 1 dose of rabies vaccine on day 0, 3, 7, 14, and 28, for a total of 5 doses.

0.5mL for each dose, manufactured by Liaoning Chengda Biotechnology CO., LTD, administered by intramuscular injection into the deltoid muscle of the lateral upper arm.

Autres noms:
  • VITESSE
Expérimental: Zagreb regimen (CD4+ T cell count <350 cells/mm³)

Eligible HIV-infected participants on stable antiretroviral therapy and with a baseline CD4+ T cell count <350 cells/mm³ will receive 2 doses of rabies vaccine on day 0, 1 dose on day 7 and 1 dose on day 21, for a total of 4 doses.

0.5mL for each dose, manufactured by Liaoning Chengda Biotechnology CO., LTD, administered by intramuscular injection into the deltoid muscle of the lateral upper arm.

Autres noms:
  • VITESSE
Expérimental: Essen regimen (CD4+ T cell count <350 cells/mm³)

Eligible HIV-infected participants on stable antiretroviral therapy and with a baseline CD4+ T cell count <350 cells/mm³ will receive 1 dose of rabies vaccine on day 0, 3, 7, 14, and 28, for a total of 5 doses.

0.5mL for each dose, manufactured by Liaoning Chengda Biotechnology CO., LTD, administered by intramuscular injection into the deltoid muscle of the lateral upper arm.

Autres noms:
  • VITESSE

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Seroconversion rate and geometric mean concentration (GMC) of rabies virus neutralizing antibodies at 14 days after completion of the full vaccination course
Délai: 14 days after completion of the full vaccination course

Seroconversion rate and GMC of rabies virus neutralizing antibodies among HIV-infected participants who are seronegative at baseline (Day 0). Seroconversion is defined as a rabies virus neutralizing antibody titer ≥0.5 IU/mL. Rabies virus neutralizing antibodies will be assessed by the rapid fluorescent focus inhibition test (RFFIT).

14 days after completion of the full vaccination course
Incidence of adverse events after vaccination
Délai: 30 minutes, 0-7 days, and 8-14 days after each vaccine dose

Incidence of immediate local and systemic adverse events recorded within 30 minutes after each vaccination; incidence of solicited local and systemic adverse events collected 0-7 days after each dose; incidence of unsolicited adverse events collected 8-14 days after each dose. Adverse events are defined as any untoward medical occurrence in a participant administered vaccine, not necessarily having a causal relationship with vaccination.

30 minutes, 0-7 days, and 8-14 days after each vaccine dose

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Seroconversion rate and GMC of rabies virus neutralizing antibodies at 14 days after the first dose of vaccination
Délai: 14 days after the first dose of vaccination

Seroconversion rate and GMC of rabies virus neutralizing antibodies at 14 days after the first dose vaccination among HIV-infected participants who are seronegative at baseline (Day 0). Seroconversion is defined as a rabies virus neutralizing antibody titer ≥0.5 IU/mL. Rabies virus neutralizing antibodies will be assessed by RFFIT.

14 days after the first dose of vaccination
Seroconversion rate and GMC of rabies virus neutralizing antibodies at 90 days after completion of the full vaccination course
Délai: 90 days after completion of the full vaccination course

Seroconversion rate and GMC of rabies virus neutralizing antibodies at 90 days after completion of the full vaccination course among HIV-infected participants who are seronegative at baseline (Day 0). Seroconversion is defined as a rabies virus neutralizing antibody titer ≥0.5 IU/mL. Rabies virus neutralizing antibodies will be assessed by RFFIT.

90 days after completion of the full vaccination course
Seroconversion rate and GMC of rabies virus neutralizing antibodies after booster vaccination
Délai: 14 days after booster vaccination

Seroconversion rate and GMC of rabies virus neutralizing antibodies 14 days after booster vaccination, in participants who remain seronegative (titer <0.5 IU/mL) at 14 days after completion of the full vaccination course. Booster vaccination consists of 2 doses administered on day 0 and day 3 of the booster phase. Seroconversion is defined as a rabies virus neutralizing antibody titer ≥0.5 IU/mL. Rabies virus neutralizing antibodies will be assessed by RFFIT.

14 days after booster vaccination
Seroconversion rate and GMC of rabies virus neutralizing antibodies at Day 28 within the Essen regimen group
Délai: Day 28 within the Essen vaccination regimen

Seroconversion rate and GMC of rabies virus neutralizing antibodies at Day 28 among HIV-infected participants who are seronegative at baseline (Day 0) and assigned to the Essen five dose regimen. Seroconversion is defined as a rabies virus neutralizing antibody titer ≥0.5 IU/mL. Rabies virus neutralising antibodies will be assessed by RFFIT.

Day 28 within the Essen vaccination regimen

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

8 août 2026

Achèvement primaire (Estimé)

30 juin 2027

Achèvement de l'étude (Estimé)

30 juin 2028

Dates d'inscription aux études

Première soumission

6 novembre 2026

Première soumission répondant aux critères de contrôle qualité

6 novembre 2026

Première publication (Réel)

12 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

12 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

6 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

INDÉCIS

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner